Inovio Pharmaceuticals (INO) Competitors $1.76 -0.01 (-0.56%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$1.79 +0.03 (+1.70%) As of 09:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INO vs. NVRO, RCEL, NYXH, INGN, ELMD, DRTS, PDEX, LNSR, BWAY, and LAKEShould you be buying Inovio Pharmaceuticals stock or one of its competitors? The main competitors of Inovio Pharmaceuticals include Nevro (NVRO), AVITA Medical (RCEL), Nyxoah (NYXH), Inogen (INGN), Electromed (ELMD), Alpha Tau Medical (DRTS), Pro-Dex (PDEX), LENSAR (LNSR), BrainsWay (BWAY), and Lakeland Industries (LAKE). These companies are all part of the "medical equipment" industry. Inovio Pharmaceuticals vs. Nevro AVITA Medical Nyxoah Inogen Electromed Alpha Tau Medical Pro-Dex LENSAR BrainsWay Lakeland Industries Inovio Pharmaceuticals (NASDAQ:INO) and Nevro (NYSE:NVRO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, community ranking, media sentiment, institutional ownership and profitability. Which has better earnings and valuation, INO or NVRO? Nevro has higher revenue and earnings than Inovio Pharmaceuticals. Nevro is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInovio Pharmaceuticals$217.76K296.36-$135.12M-$3.99-0.44Nevro$408.52M0.55-$92.21M-$3.05-1.92 Do institutionals and insiders hold more shares of INO or NVRO? 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.5% of Nevro shares are owned by institutional investors. 2.5% of Inovio Pharmaceuticals shares are owned by company insiders. Comparatively, 3.2% of Nevro shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, INO or NVRO? Inovio Pharmaceuticals has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Comparatively, Nevro has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Is INO or NVRO more profitable? Inovio Pharmaceuticals has a net margin of 0.00% compared to Nevro's net margin of -16.54%. Nevro's return on equity of -23.52% beat Inovio Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Inovio PharmaceuticalsN/A -118.17% -83.47% Nevro -16.54%-23.52%-10.83% Does the media refer more to INO or NVRO? In the previous week, Inovio Pharmaceuticals had 4 more articles in the media than Nevro. MarketBeat recorded 6 mentions for Inovio Pharmaceuticals and 2 mentions for Nevro. Inovio Pharmaceuticals' average media sentiment score of 0.27 beat Nevro's score of 0.23 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nevro 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in INO or NVRO? Inovio Pharmaceuticals received 216 more outperform votes than Nevro when rated by MarketBeat users. Likewise, 70.94% of users gave Inovio Pharmaceuticals an outperform vote while only 62.38% of users gave Nevro an outperform vote. CompanyUnderperformOutperformInovio PharmaceuticalsOutperform Votes72070.94% Underperform Votes29529.06% NevroOutperform Votes50462.38% Underperform Votes30437.62% Do analysts rate INO or NVRO? Inovio Pharmaceuticals currently has a consensus target price of $12.20, suggesting a potential upside of 593.18%. Nevro has a consensus target price of $5.36, suggesting a potential downside of 8.29%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Inovio Pharmaceuticals is more favorable than Nevro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inovio Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Nevro 2 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.92 SummaryInovio Pharmaceuticals beats Nevro on 11 of the 18 factors compared between the two stocks. Remove Ads Get Inovio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INO vs. The Competition Export to ExcelMetricInovio PharmaceuticalsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.90M$4.07B$5.33B$7.57BDividend YieldN/A39.49%5.11%4.32%P/E Ratio-0.4427.6321.7217.82Price / Sales296.3650.20376.8894.61Price / CashN/A51.0838.1534.64Price / Book0.345.826.474.00Net Income-$135.12M$67.09M$3.20B$247.23M7 Day Performance10.69%-0.17%2.86%1.45%1 Month Performance-13.30%-3.20%-8.55%-6.24%1 Year Performance-81.73%14.84%10.58%0.60% Inovio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INOInovio Pharmaceuticals3.42 of 5 stars$1.76-0.6%$12.20+593.2%-84.0%$64.90M$217,756.00-0.44320Short Interest ↑NVRONevro0.8674 of 5 stars$5.85+0.1%$6.43+9.9%-53.2%$224.32M$408.52M-3.091,215Analyst ForecastRCELAVITA Medical1.4531 of 5 stars$7.76+3.5%$17.25+122.3%-2.4%$203.45M$64.25M-3.25130NYXHNyxoah2.0553 of 5 stars$5.71-6.1%$14.75+158.3%-32.8%$194.48M$4.52M-3.05110Short Interest ↑Gap DownINGNInogen3.1608 of 5 stars$7.09+0.7%$7.00-1.3%+0.6%$190.63M$335.71M-3.151,030Short Interest ↓News CoveragePositive NewsHigh Trading VolumeELMDElectromed1.1536 of 5 stars$22.16-1.0%$38.00+71.5%+59.5%$189.62M$59.63M29.55160Positive NewsDRTSAlpha Tau Medical2.8247 of 5 stars$2.45-2.8%$8.00+226.5%-7.9%$172.43MN/A-5.7080Short Interest ↓Gap DownHigh Trading VolumePDEXPro-Dex1.5192 of 5 stars$52.87+3.9%$52.00-1.6%+237.1%$172.41M$61.00M26.30140Short Interest ↑News CoveragePositive NewsHigh Trading VolumeLNSRLENSAR1.9002 of 5 stars$13.76-0.6%$15.00+9.0%+328.6%$162.22M$53.49M-9.42110Short Interest ↓High Trading VolumeBWAYBrainsWay3.6444 of 5 stars$8.61-2.7%$13.17+52.9%+58.4%$162.10M$41.02M86.11120Short Interest ↓Positive NewsGap DownLAKELakeland Industries4.8796 of 5 stars$16.89-5.4%$28.25+67.3%-0.6%$160.44M$151.82M-187.671,800 Remove Ads Related Companies and Tools Related Companies Nevro Alternatives AVITA Medical Alternatives Nyxoah Alternatives Inogen Alternatives Electromed Alternatives Alpha Tau Medical Alternatives Pro-Dex Alternatives LENSAR Alternatives BrainsWay Alternatives Lakeland Industries Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INO) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inovio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inovio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INO Stock Free INO Stock Alerts